Cipla Ltd.90th Year Milestone with Strong Growth Ahead

Cipla concluded FY26 with total revenue of ₹28,163 crores, marking its 90th anniversary year with significant milestones across all business segments.

The One India business surpassed ₹12,500 crores with nine percent annual growth, while posting robust fifteen percent growth in Q4. North America revenues reached $780 million, with the strategic inflection point of generic Ventolin approval from the U.S. facility expected to launch in Q1 FY27. EBITDA margin stood at twenty-one percent for FY26, with management guiding 18.5 to 20 percent for FY27, expecting sequential quarterly improvement with H2 delivering above twenty percent.

The company targets a $1 billion U.S. exit run rate by end-FY27, driven by four respiratory launches and one major peptide product. Management outlined an ambitious pipeline of 40-50 U.S. product filings over the next three years, including twelve first-to-files. Cipla is also entering biosimilars, targeting the $200 billion opportunity with two global assets already under development. The company maintains a strong net cash position of ₹10,526 crores and ROIC of 22.9 percent.